Testicular Neoplasms Clinical Trial
Official title:
Sequential High-Dose Chemotherapy Combining Two Mobilization and Cyto-Reductive Treatments Followed by Three High-Dose Chemotherapy Regimens Supported by Autologous Stem Cell Transplantation
Verified date | March 2007 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
High-dose chemotherapy (HD-CT) is able to circumvent platinum-resistance of
resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New
strategies are needed with new drugs and a sequential approach.
Patients with relapsed (but not absolutely refractory to Cisplatinum-based chemotherapy)
poor-prognosis GCTs are scheduled to receive 2 cycles combining epirubicin and paclitaxel
followed by 3 consecutive HD-CT supported by stem cell transplantation. One course will
combine Taxol, 360 mg/m² + thiotepa, 720 mg/m², followed by two ICE regimens (Ifosfamide, 12
g/m², carboplatin, AUC 20, etoposide, 1500 mg/m²).
This phase II study is designed as a Gehan method. The main objective of the study is the
complete response rate. With this aim in view, it is planned to enroll in its first step 14
patients to insure that if no complete response (CR) is noticed, study would be stopped for
inefficacy (i.e., a CR rate lower than 20%). If one or more CR are noticed, protocol
specified that up to 45 patients will be included in order to reduce the confidence interval
(CI) of the CR rate. Secondary objectives are the overall response rate (RR), the overall
survival (OS) and the progression-free survival (PFS) rates, toxicity and toxic death rate.
The statistical analysis is done in terms of intent-to-treat.
Status | Completed |
Enrollment | 50 |
Est. completion date | January 2010 |
Est. primary completion date | January 2010 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: Eligibility requirements includes the following criteria: - Age >18 years and < 65 - Performance status < 3 - Histologically or biologically documented GCTs - Testicular, abdominal, or mediastinal tumors - Measurable or evaluable disease - Life expectancy > 3 months - Normal cardiac, liver, and renal function tests - Absence of infection - HIV negative test - Signed informed consent - All patients had to have been previously treated with at least one line of a cisplatin-containing regimen and were included if they were refractory after one or two line(s) of cisplatin-based CT, or had relapsed after two lines of a cisplatin-based CT Exclusion Criteria: - Fireproof diseases (progress unless month with regard to the last cycle of chemotherapy or in the course of chemotherapy) - Relapses after complete answer obtained by surgery ( sCR ) - Neuropathy of superior rank or = II - renal Function (Office) superior creatinine or = 125 mmol/l and/or clearance of the creatinine subordinate or = II 60ml / mn - Antecedents of congestive even compensated cardiac insufficiency - Hurts of growing teratoma that is measurable hurts increasing by size (cutting) in the absence of rise of marker pens - Extensive chemotherapy with support of haematopoietic stem cells. NB: A previous preventive irradiation under diaphragmatitis for a seminoma stage I (dose from 24 to 30 Gy in classic spreading) does not establish one against formal indication. However, an estimation clarifies capacities of the haematopoietic marrow is recommended with observation of the evolution of the NFP in the course of chemotherapy and quantification of cells CD 34 + in the peripheral blood. It's the same of the case where a chemotherapy by carboplatine was realized |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Hôpital TENON, Service d'Oncologie Médicale | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Amgen, Baxter Healthcare Corporation, Ministry of Health, France |
France,
Lotz JP, Bui B, Gomez F, Théodore C, Caty A, Fizazi K, Gravis G, Delva R, Peny J, Viens P, Duclos B, De Revel T, Curé H, Gligorov J, Guillemaut S, Ségura C, Provent S, Droz JP, Culine S, Biron P; Groupe d'Etudes des Tumeurs Uro-Génitales (GETUG). Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol. 2005 Mar;16(3):411-8. Epub 2005 Jan 19. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete response rate | Complete response rate | during de study | Yes |
Secondary | Survival (overall and progression-free), toxicity, toxic-death rate. | Survival (overall and progression-free), toxicity, toxic-death rate. | during the study | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Terminated |
NCT02577172 -
Testicular Cancer and Aerobic and Strength Training
|
N/A | |
Completed |
NCT03403777 -
Avelumab in Refractory Testicular Germ Cell Cancer.
|
Phase 2 | |
Completed |
NCT02890030 -
The Platinum Study Comparison Group
|
||
Recruiting |
NCT05264337 -
Lymphedema After Urologic Surgery
|
||
Active, not recruiting |
NCT03426865 -
Role of Axumin PET Scan in Germ Cell Tumor
|
||
Completed |
NCT00001270 -
Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma
|
Phase 1 | |
Completed |
NCT02459132 -
High-Intensity Aerobic Interval Training in Testicular Cancer Survivors
|
N/A | |
Completed |
NCT06309732 -
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
|
Phase 2 | |
Terminated |
NCT02499952 -
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
|
Phase 2 | |
Recruiting |
NCT02304575 -
Quality of Life Among Testicular Cancer Survivors
|
N/A | |
Withdrawn |
NCT02492360 -
Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy
|
N/A | |
Completed |
NCT04122430 -
Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours
|
||
Recruiting |
NCT02229916 -
Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
|
||
Completed |
NCT02161692 -
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
|
Phase 2 | |
Completed |
NCT02966509 -
Engagement of Patients With Advanced Cancer
|
N/A | |
Recruiting |
NCT02341989 -
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
|
Phase 3 | |
Completed |
NCT05056688 -
Effect of Online Education Given to Young Adults on Testicular Cancer Health Beliefs and Behaviors
|
N/A | |
Terminated |
NCT05229900 -
A Study of SGN-ALPV in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00123773 -
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
|
Phase 2 |